Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults
Shots:
- The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D
- The study showed reduction in MACE events and the profile of Trulicity was consistent with the GLP-1 receptor agonist (RA) class
- Trulicity is an injectable prescription medicine for adults with T2D used for the improving blood sugar level and reduction of MACE
Click here to read full press release/ article
Ref: Eli Lilly | Image: Eli Lilly
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com